×
About 337 results

ALLMedicine™ Dysfibrinogenemia Center

Research & Reviews  167 results

How I treat dysfibrinogenemia.
https://doi.org/10.1182/blood.2020010116
Blood Casini A, de Moerloose P

Apr 25th, 2021 - Congenital dysfibrinogenemia (CD) is caused by structural changes in fibrinogen that modify its function. Diagnosis is based on discrepancy between decreased fibrinogen activity and normal fibrinogen antigen levels and is confirmed by genetic test...

Effects of pathogen reduction technology and storage duration on the ability of cryopre...
https://doi.org/10.1111/trf.16376
Transfusion Thomas KA, Shea SM et. al.

Mar 23rd, 2021 - Fibrinogen concentrates and cryoprecipitate are currently used for fibrinogen supplementation in bleeding patients with dysfibrinogenemia. Both products provide an abundant source of fibrinogen but take greater than 10 min to prepare for administr...

Congenital dysfibrinogenemia caused by γAla327Val mutation: structural abnormality of D...
https://doi.org/10.1080/16078454.2021.1893977
Hematology (Amsterdam, Netherlands); Wei A, Wu Y et. al.

Mar 5th, 2021 - : Congenital dysfibrinogenemia (CD) is a coagulation disorder caused by mutations in the fibrinogen genes, which result in abnormal fibrinogen function. However, the precise pathogenesis underlying it remains unclear. : In this study, we identifie...

Comparison of different activators of coagulation by turbidity analysis of hereditary d...
https://doi.org/10.1097/MBC.0000000000001000
Blood Coagulation & Fibrinolysis : an International Journ... Marchi R, Neerman-Arbez M et. al.

Jan 14th, 2021 - Turbidity analysis is widely used as a quantitative technique in hereditary dysfibrinogenemia. We aimed to compare several coagulation triggers in hereditary dysfibrinogenemia and control plasmas. We included 20 patients with hereditary dysfibrino...

Screening method for congenital dysfibrinogenemia using clot waveform analysis with the...
https://doi.org/10.1111/ijlh.13358
International Journal of Laboratory Hematology; Arai S, Kamijo T et. al.

Oct 8th, 2020 - Congenital fibrinogen disorders (CFDs) are classified as afibrinogenemia or hypofibrinogenemia (Hypo), dysfibrinogenemia (Dys), or hypodysfibrinogenemia (Hypodys), according to functional and antigenic fibrinogen concentrations. However, in routin...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  169 results

How I treat dysfibrinogenemia.
https://doi.org/10.1182/blood.2020010116
Blood Casini A, de Moerloose P

Apr 25th, 2021 - Congenital dysfibrinogenemia (CD) is caused by structural changes in fibrinogen that modify its function. Diagnosis is based on discrepancy between decreased fibrinogen activity and normal fibrinogen antigen levels and is confirmed by genetic test...

Effects of pathogen reduction technology and storage duration on the ability of cryopre...
https://doi.org/10.1111/trf.16376
Transfusion Thomas KA, Shea SM et. al.

Mar 23rd, 2021 - Fibrinogen concentrates and cryoprecipitate are currently used for fibrinogen supplementation in bleeding patients with dysfibrinogenemia. Both products provide an abundant source of fibrinogen but take greater than 10 min to prepare for administr...

Congenital dysfibrinogenemia caused by γAla327Val mutation: structural abnormality of D...
https://doi.org/10.1080/16078454.2021.1893977
Hematology (Amsterdam, Netherlands); Wei A, Wu Y et. al.

Mar 5th, 2021 - : Congenital dysfibrinogenemia (CD) is a coagulation disorder caused by mutations in the fibrinogen genes, which result in abnormal fibrinogen function. However, the precise pathogenesis underlying it remains unclear. : In this study, we identifie...

Comparison of different activators of coagulation by turbidity analysis of hereditary d...
https://doi.org/10.1097/MBC.0000000000001000
Blood Coagulation & Fibrinolysis : an International Journ... Marchi R, Neerman-Arbez M et. al.

Jan 14th, 2021 - Turbidity analysis is widely used as a quantitative technique in hereditary dysfibrinogenemia. We aimed to compare several coagulation triggers in hereditary dysfibrinogenemia and control plasmas. We included 20 patients with hereditary dysfibrino...

Fibryga - fibrinogen (human) kit-Octapharma USA Inc
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=007a93f4-d84b-1fa9-51ed-32f6140bf423

Dec 21st, 2020 - FIBRYGA is a human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. FIBRYGA is not indicated for dysfibrin...

see more →